177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?
- 395 Downloads
Compliance with ethical standards
The University of Münster received consulting fees from ABX Advanced Biochemical Compounds, Radeberg, Germany, for KR and MB. The authors declare they have no conflicts of interest according to the subject and matter of the presented article.
Conflict of interest
The authors declare that they have no financial or non-financial competing interests.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
- 2.Hofman MS, Sandhu S, Eu P, Price J, Akhrust T, Iravani A, et al. Lutetium-177 PSMA (LuPSMA) theranostics phase II trial: efficacy, safety and QoL in patients with castrate-resistant prostate cancer treated with LuPSMA. Ann Oncol. 2017;28(Suppl 5).Google Scholar
- 3.Rahbar K, Boegemann M, Yordanova A, Eveslage M, Schafers M, Essler M, et al. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival. Eur J Nucl Med Mol Imaging. 2017.Google Scholar